Home Physical Sciences 7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS
Chapter
Licensed
Unlicensed Requires Authentication

7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS

  • Angela Casini , Raymond Wai-Yin Sun and Ingo Ott
Become an author with De Gruyter Brill

Abstract

Since ancient times gold and its complexes have been used as therapeutics against different diseases. In modern medicine gold drugs have been applied for the treatment of rheumatoid arthritis, however, recently other medical applications have come into the focus of inorganic medicinal chemistry. This chapter provides a non-comprehensive overview of key developments in the field of gold anticancer drugs. Exciting findings on gold(I) and gold(III) complexes as antitumor agents are summarized together with a discussion of relevant aspects of their modes of action.

Abstract

Since ancient times gold and its complexes have been used as therapeutics against different diseases. In modern medicine gold drugs have been applied for the treatment of rheumatoid arthritis, however, recently other medical applications have come into the focus of inorganic medicinal chemistry. This chapter provides a non-comprehensive overview of key developments in the field of gold anticancer drugs. Exciting findings on gold(I) and gold(III) complexes as antitumor agents are summarized together with a discussion of relevant aspects of their modes of action.

Chapters in this book

  1. Frontmatter i
  2. About the Editors v
  3. Historical Development and Perspectives of the Series vii
  4. Preface to Volume 18 ix
  5. Contents xiii
  6. Contributors to Volume 18 xix
  7. Titles of Volumes 1–44 in the Metal Ions in Biological Systems Series xxiii
  8. Contents of Volumes in the Metal Ions in Life Sciences Series xxv
  9. 1. CISPLATIN AND OXALIPLATIN: OUR CURRENT UNDERSTANDING OF THEIR ACTIONS 1
  10. 2. POLYNUCLEAR PLATINUM COMPLEXES. STRUCTURAL DIVERSITY AND DNA BINDING 43
  11. 3. PLATINUM(IV) PRODRUGS 69
  12. 4. METALLOGLYCOMICS 109
  13. 5. THE DECEPTIVELY SIMILAR RUTHENIUM(III) DRUG CANDIDATES KP1019 AND NAMI-A HAVE DIFFERENT ACTIONS. WHAT DID WE LEARN IN THE PAST 30 YEARS? 141
  14. 6. MULTINUCLEAR ORGANOMETALLIC RUTHENIUM-ARENE COMPLEXES FOR CANCER THERAPY 171
  15. 7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS 199
  16. 8. COORDINATION COMPLEXES OF TITANIUM(IV) FOR ANTICANCER THERAPY 219
  17. 9. HEALTH BENEFITS OF VANADIUM AND ITS POTENTIAL AS AN ANTICANCER AGENT 251
  18. 10. GALLIUM COMPLEXES AS ANTICANCER DRUGS 281
  19. 11. NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES 303
  20. 12. NUCLEIC ACID QUADRUPLEXES AND METALLO-DRUGS 325
  21. 13. ANTITUMOR METALLODRUGS THAT TARGET PROTEINS 351
  22. 14. METALLOINTERCALATORS AND METALLOINSERTORS: STRUCTURAL REQUIREMENTS FOR DNA RECOGNITION AND ANTICANCER ACTIVITY 387
  23. 15. IRON AND ITS ROLE IN CANCER DEFENSE: A DOUBLE-EDGED SWORD 437
  24. 16. COPPER COMPLEXES IN CANCER THERAPY 469
  25. 17. TARGETING ZINC(II) SIGNALLING TO PREVENT CANCER 507
  26. SUBJECT INDEX 531
Downloaded on 21.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/9783110470734-007/html?lang=en&srsltid=AfmBOopRLyOPhP9MoT1mtMfvmoc3gcXldEDmHWVOYD1-WqQ_PC5tkXqB
Scroll to top button